Hans K Breddin

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Can platelet aggregometry be standardized?
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, Germany
    Platelets 16:151-8. 2005
  2. ncbi Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany
    N Engl J Med 344:626-31. 2001
  3. ncbi [The value of platelet function tests]
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main
    Vasa 32:123-9. 2003
  4. ncbi [Can acetylsalicylic acid be used for the treatment of venous diseases?]
    Hans Klaus Breddin
    Dtsch Med Wochenschr 128:1499. 2003
  5. ncbi Current developments in antithrombotic therapy: the role of antithrombin agents
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases eV, Frankfurt, Germany
    Pathophysiol Haemost Thromb 32:1-8. 2002
  6. ncbi Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis
    Hans K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, Germany
    Thromb Haemost 89:272-7. 2003
  7. ncbi [Experimental and clinical results with the thrombin inhibitor Argatroban]
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, Germany
    Hamostaseologie 22:55-9. 2002
  8. ncbi Reviparin sodium - a new low molecular weight heparin
    Hans Klaus Breddin
    International Institute of Thrombosis and Vascular Diseases e V, Ferdinand Schrey Weg 6, D 60598 Frankfurt am Main, Germany
    Expert Opin Pharmacother 3:173-82. 2002
  9. ncbi Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers
    Hans Ulrich Esslinger
    Abbott GmbH and Co KG, Ludwigshafen, Germany
    Clin Appl Thromb Hemost 9:79-88. 2003
  10. ncbi Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans
    Jochen Graff
    Institute of Clinical Pharmacology, University Hospital Frankfurt, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Br J Clin Pharmacol 56:321-6. 2003

Collaborators

Detail Information

Publications14

  1. ncbi Can platelet aggregometry be standardized?
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, Germany
    Platelets 16:151-8. 2005
    ..If some rules are applied aggregometry is a relatively simple and reliable method, and well suited for clinical studies and for experimental research...
  2. ncbi Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt, Germany
    N Engl J Med 344:626-31. 2001
    ..Low-molecular-weight heparins are frequently used to treat venous thromboembolism, but optimal dosing regimens and clinical outcomes need further definition...
  3. ncbi [The value of platelet function tests]
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main
    Vasa 32:123-9. 2003
    ..Platelet induced thrombin generation is an interesting function to measure drug effects. None of the presently available platelet function tests is well standardized, so there is much room for improvement...
  4. ncbi [Can acetylsalicylic acid be used for the treatment of venous diseases?]
    Hans Klaus Breddin
    Dtsch Med Wochenschr 128:1499. 2003
  5. ncbi Current developments in antithrombotic therapy: the role of antithrombin agents
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases eV, Frankfurt, Germany
    Pathophysiol Haemost Thromb 32:1-8. 2002
    ..It is likely that in the future thrombin inhibitors will replace other forms of anticoagulation in a number of indications...
  6. ncbi Risk factors and coagulation parameters in relationship to phlebographic response and clinical outcome in the treatment of acute deep vein thrombosis
    Hans K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, Germany
    Thromb Haemost 89:272-7. 2003
    ..Significant differences in Marder score and coagulation parameters at baseline were found between responders and nonresponders. Non-responders have a higher risk tosuffer recurrent VTE and may need intensified treatment...
  7. ncbi [Experimental and clinical results with the thrombin inhibitor Argatroban]
    H K Breddin
    International Institute of Thrombosis and Vascular Diseases, Frankfurt am Main, Germany
    Hamostaseologie 22:55-9. 2002
    ..The specific inhibition of thrombin can be measured with the ECT (ecarin clotting time)...
  8. ncbi Reviparin sodium - a new low molecular weight heparin
    Hans Klaus Breddin
    International Institute of Thrombosis and Vascular Diseases e V, Ferdinand Schrey Weg 6, D 60598 Frankfurt am Main, Germany
    Expert Opin Pharmacother 3:173-82. 2002
    ..The use of reviparin is associated with a similar or lower incidence of bleeding complications than UFH...
  9. ncbi Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers
    Hans Ulrich Esslinger
    Abbott GmbH and Co KG, Ludwigshafen, Germany
    Clin Appl Thromb Hemost 9:79-88. 2003
    ..None of the clotting parameters or platelet function tests correlated with the prolongation of the bleeding time...
  10. ncbi Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans
    Jochen Graff
    Institute of Clinical Pharmacology, University Hospital Frankfurt, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Br J Clin Pharmacol 56:321-6. 2003
    ..To investigate the pharmacodynamic interaction of unfractionated heparin (UFH) and acetylic salicylic acid (ASA) on YM337, a monoclonal humanized antibody of the platelet GPIIb/IIIa receptor...
  11. ncbi [Yesterday, today and tomorrow. Anticoagulants in review]
    Sebastian Harder
    , Pharmazentrum Frankfurt,
    Pharm Unserer Zeit 33:172-80. 2004
  12. ncbi Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia
    Hans Klaus Breddin
    Arch Pathol Lab Med 127:782-3; author reply 783. 2003
  13. ncbi Acetylsalicylic acid tablets with glycine improve long-term tolerability in antiplatelet drug therapy: results of a noninterventional trial
    Werner Kusche
    A. CRO Clinical Research Services GmbH, Wiesbaden, Germany
    Adv Ther 20:237-45. 2003
    ..With respect to long-term treatment compliance, the improved tolerability profile observed with this Gly-ASA preparation indicates an important advantage over nonglycine-containing ASA alternatives...
  14. ncbi [Obituary: in memoriam Hans Klaus Breddin]
    Sylvia Haas
    Hamostaseologie 26:349. 2006